InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (13 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
13
T+90 hit rate
22%
T+90 mean return
-4.5%
Across 18 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by GRAHAM RICHARD A, SVP, Développement. Director active across 1 company, notably Theravance Biopharma, Inc.. Cumulatively, 33 filings have been published. Breakdown: 0 buy · 13 sells. Total volume traded: €424k. History available since 20 May 2021. The latest transaction was disclosed on 20 February 2024 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations33 total
19,294 shares@ US$8.927.8% of flowOrdinary SharesSEC:0001415889-24-004960:0
12,630 shares@ US$10.375.9% of flowOrdinary SharesSEC:0001415889-23-015448:0
2,482 shares@ US$10.221.2% of flowOrdinary SharesSEC:0001415889-23-015228:0
15,000 shares0Ordinary SharesSEC:0001415889-23-014680:0
2,482 shares@ US$9.031.0% of flowOrdinary SharesSEC:0001415889-23-014412:0
2,482 shares@ US$9.891.2% of flowOrdinary SharesSEC:0001415889-23-013342:0
10,461 shares@ US$9.704.6% of flowOrdinary SharesSEC:0001415889-23-012514:0
2,322 shares@ US$9.991.0% of flowOrdinary SharesSEC:0001415889-23-012271:0
2,322 shares@ US$9.841.0% of flowOrdinary SharesSEC:0001415889-23-011244:0
2,322 shares@ US$10.691.1% of flowOrdinary SharesSEC:0001415889-23-009963:0
10,460 shares@ US$11.215.3% of flowOrdinary SharesSEC:0001415889-23-008670:0
2,322 shares@ US$11.261.2% of flowOrdinary SharesSEC:0001415889-23-008228:0
2,323 shares@ US$11.881.2% of flowOrdinary SharesSEC:0001415889-23-006620:0
2,323 shares@ US$10.321.1% of flowOrdinary SharesSEC:0001415889-23-005044:0
2,323 shares@ US$10.051.1% of flowOrdinary SharesSEC:0001415889-23-004552:0
75,000 shares0Ordinary SharesSEC:0001415889-23-004271:0
12,057 shares@ US$10.445.8% of flowOrdinary SharesSEC:0001415889-23-003065:0
2,084 shares@ US$10.731.0% of flowOrdinary SharesSEC:0001415889-22-012077:0
27,350 shares@ US$10.8514.0% of flowOrdinary SharesSEC:0001415889-22-011669:0
2,800 shares@ US$11.201.5% of flowOrdinary SharesSEC:0001415889-22-011523:0
18,991 shares@ US$9.348.6% of flowOrdinary SharesSEC:0001415889-22-008981:0
4,906 shares@ US$9.71052.3% of flowOrdinary SharesSEC:0001415889-22-008835:0
15,086 shares@ US$8.796.3% of flowOrdinary SharesSEC:0001415889-22-008512:0
3,947 shares@ US$8.740.0039% mcap6.1% of flowOrdinary SharesSEC:0001415889-22-005629:0
20,377 shares@ US$9.610.021% mcap32.4% of flowOrdinary SharesSEC:0001415889-22-001697:0
25 of 33 declarations
About GRAHAM RICHARD A
Richard A. Graham is Senior Vice President, Development at Theravance Biopharma, Inc., a biopharmaceutical company focused on innovation. In his role, he oversees product development and research initiatives, ensuring the company remains at the forefront of medical advancements. His expertise in strategic development is essential to Theravance's mission.
